Finance

Results: 3433-3444 of 44129

PR Newswire associated0

CATL and HyperStrong Sign the World's Largest Sodium-Ion Energy Storage Cooperation Agreement

Dr. Vivek Mundada with Medcare multidisciplinary medical team (Photo: AETOSWire)

Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US

QSA Global and Perpetual Atomics Team

Perpetual Atomics and QSA Global Fuel the World’s First Americium-Powered Radioisotope Heater Unit Core

Alipay Launches AI Payment Processing Product to Help Businesses and OPCs Thrive in the Agentic Economy

HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning.

HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI

Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture

PR Newswire associated0

ASSAÍ ENDS FIRST QUARTER WITH CONSISTENT CASH GENERATION, LEVERAGE REDUCTION, AND MARKET SHARE GAINS

BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs

PR Newswire associated0

NYSE Content Update: Joby Aviation Rings Opening Bell Following NYC Test Flight

Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right)

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder

World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care